07:58 AM EST, 12/11/2024 (MT Newswires) -- Relay Therapeutics ( RLAY ) said Wednesday updated interim clinical data from its first-in-human study of RLY-2608 in combination with fulvestrant showed "clinically meaningful" progression-free survival in patients with locally advanced or metastatic breast cancer.

The updated data showed a median progression-free survival of 11.4 months in second-line patients who received a 600-milligram dosage of RLY-2608 twice a day plus fulvestrant, the company said, adding its RLY-2608 and fulvestrant arm enrolled 118 patients, and was "generally well tolerated."

The company plans to start a pivotal study of RLY-2608 plus fulvestrant in 2025, with data from the phase 1/2 study to be released the same year.

Relay Therapeutics ( RLAY ) shares were up nearly 6% in recent Wednesday premarket activity.